A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.
Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK.
Trudel S, et al. Among authors: sweet j.
Cancer Gene Ther. 2003 Oct;10(10):755-63. doi: 10.1038/sj.cgt.7700626.
Cancer Gene Ther. 2003.
PMID: 14502228
Clinical Trial.